Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Response Genetics, Inc. Announces Proposed Underwritten Public Offering



Response Genetics, Inc. Announces Proposed Underwritten Public Offering

LOS ANGELES, Dec. 12, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc.
(Nasdaq:RGDX) (the "Company"), a company focused on the development and sale
of molecular diagnostic tests that help determine a patient's response to
cancer therapy, announced today it intends to offer and sell registered shares
of its common stock in an underwritten public offering. The Company expects to
use the net proceeds of the offering for working capital and general corporate
purposes. 

National Securities Corporation, a wholly owned subsidiary of National
Holdings, Inc. (OTCBB:NHLD), is serving as the sole underwriter of the
offering.

The securities described above are being offered by the Company pursuant to an
effective shelf registration statement, including a base prospectus, filed
with the Securities and Exchange Commission (the "SEC") on Form S-3 (File No.
333-171266) on December 17, 2010, as amended.  A preliminary prospectus
supplement related to the offering has been filed with the SEC and is
available on the SEC's website located at http://www.sec.gov.  Copies of the
preliminary prospectus supplement and the accompanying base prospectus may be
obtained by contacting the underwriter at the following address:

National Securities Corporation
410 Park Avenue, 14th Floor
New York, NY 10022
Attn: Kim Addarich
Telephone: (212)-417-8164 
Email: prospectusrequest@nationalsecurities.com

A final prospectus supplement describing the terms of the offering will be
filed with the SEC. Any offer will be made, if at all, only by means of a
prospectus supplement and accompanying base prospectus forming a part of the
effective registration statement. Before investing, you should read the
prospectus supplement and the accompanying base prospectus, and other
documents that the Company has filed or will file with the SEC, for
information about the Company and this offering.

This communication shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sales of these securities in any
state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.

About Response Genetics, Inc.

Response Genetics, Inc. is a CLIA-certified clinical laboratory focused on the
development and sale of molecular diagnostic testing services for cancer.  The
Company's technologies enable extraction and analysis of genetic information
derived from tumor cells stored as formalin-fixed and paraffin-embedded
specimens.  The Company's principal customers include oncologists and
pathologists.  In addition to diagnostic testing services, the Company
generates revenue from the sale of its proprietary analytical pharmacogenomic
testing services of clinical trial specimens to the pharmaceutical industry.
 The Company's headquarters is located in Los Angeles, California.  

Forward-Looking Statements Notice

This press release contains certain "forward-looking statements" related to
the businesses of Response Genetics, Inc. which can be identified by the use
of forward-looking terminology such as "believes," "expects," "plans" or
similar expressions, including expectations regarding completion of and
anticipated proceeds from the proposed public offering, and the planned use of
such proceeds. Such forward-looking statements involve known and unknown risks
and uncertainties, including, but not limited to, whether or not the Company
will consummate the offering, the anticipated use of the proceeds of the
offering, which could change as a result of market conditions or for other
reasons, and the impact of general economic, industry or political conditions
in the United States or internationally. Certain of these risks and
uncertainties are or will be described in greater detail in our public filings
with the SEC. The Company is not under obligation to (and expressly disclaims
any such obligation to) update or alter its forward-looking statements whether
as a result of new information, future events or otherwise.

CONTACT: Investor Relations Contact:
         Peter Rahmer
         Trout Group
         646-378-2973
        
         Company Contact:
         Thomas A. Bologna
         Chairman & Chief Executive Officer
         323-224-3900

Response Genetics Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement